A- A A+

Outpatient Rapid Microinduction of Sublingual Buprenorphine in 3 Days From Methadone for Opioid Use Disorder. 

Salapenka I, Konakanchi JS, Sethi R. 

Prim Care Companion CNS Disord. 2022 Dec 27;24(6):21cr03150. doi: 10.4088/PCC.21cr03150. PMID: 36584361.

https://www.psychiatrist.com/pcc/addiction/outpatient-rapid-microinduction-of-sublingual-buprenorphine-in-3-days-from-methadone-for-opioid-use-disorder/

Buprenorphine Microdosing Cross Tapers: A Time for Change. 

Raheemullah A, Benhamou OM, Kuo J, Lembke A. 

Int J Environ Res Public Health. 2022 Dec 8;19(24):16436. doi: 10.3390/ijerph192416436. PMID: 36554317; PMCID: PMC9778657.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9778657/

Effects of buprenorphine on opioid craving in comparison to other medications for opioid use disorder: A systematic review of randomized controlled trials. 

Baxley C, Borsari B, Reavis JV, Manuel JK, Herbst E, Becker W, Pennington D, Batki SL, Seal K. 

Addict Behav. 2022 Dec 17;139:107589. doi: 10.1016/j.addbeh.2022.107589. Epub ahead of print. PMID: 36565531.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36565531/

Transferring patients from high-dose methadone to buprenorphine: A retrospective case series. 

Foran A, Tremonti C, Balgobind V, Sakr H, Murnion B. 

J Opioid Manag. 2022 Nov-Dec;18(6):557-566. doi: 10.5055/jom.2022.0752. PMID: 36523207.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36523207/

Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder. 

Laffont CM, Ngaimisi E, Gopalakrishnan M, Ivaturi V, Young M, Greenwald MK, Heidbreder C. 

Front Pharmacol. 2022 Nov 18;13:1052113. doi: 10.3389/fphar.2022.1052113. PMID: 36467036; PMCID: PMC9715596.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9715596/

Suboxone: History, controversy, and open questions. 

Sivils A, Lyell P, Wang JQ, Chu XP. 

Front Psychiatry. 2022 Oct 28;13:1046648. doi: 10.3389/fpsyt.2022.1046648. PMID: 36386988; PMCID: PMC9664560.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664560/

Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation. 

Lowry N, Cowden F, Day E, Gilvarry E, Johnstone S, Murray R, Kelleher M, Mitcheson L, Marsden J. 

BMJ Open. 2022 Oct 21;12(10):e067194. doi: 10.1136/bmjopen-2022-067194. PMID: 36270754; PMCID: PMC9594511.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594511/

Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review. 

Bozinoff N, Tardelli V, Rubin-Kahana DS, Le Foll B. 

Harm Reduct J. 2022 Oct 13;19(1):113. doi: 10.1186/s12954-022-00695-5. PMID: 36229831; PMCID: PMC9559254.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9559254/

Factors that distinguish opioid withdrawal during induction with buprenorphine microdosing: a configurational analysis. 

K K A, E J M, D M S. 

Addict Sci Clin Pract. 2022 Oct 4;17(1):55. doi: 10.1186/s13722-022-00336-z. PMID: 36195895; PMCID: PMC9531395.

https://ascpjournal.biomedcentral.com/articles/10.1186/s13722-022-00336-z

How do I interpret and use quantitative buprenorphine and norbuprenorphine urine levels? 

Waters RC, Perez M. 

Cleve Clin J Med. 2022 Oct 3;89(10):557-560. doi: 10.3949/ccjm.89a.21019. PMID: 36192022.

https://www.ccjm.org/content/89/10/557.long

Psychological pain and suicidal behavior: A review. 

Baryshnikov I, Isometsä E. 

Front Psychiatry. 2022 Aug 22;13:981353. doi: 10.3389/fpsyt.2022.981353. PMID: 36203837; PMCID: PMC9531162.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531162/

Do buprenorphine doses and ratios matter in medication assisted treatment adherence. 

Kavanagh K, Tallian K, Sepulveda JA, Rojas S, Martin S, Sikand H. 

Ment Health Clin. 2022 Aug 23;12(4):241-246. doi: 10.9740/mhc.2022.08.241. PMID: 36071736; PMCID: PMC9405633.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405633/

Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder. Adv Drug 

Namchuk AB, Lucki I, Browne CA. 

Alcohol Res. 2022;2:10254. doi: 10.3389/adar.2022.10254. Epub 2022 Feb 21. PMID: 36177442; PMCID: PMC9518754.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518754/

Transitioning From High-dose Methadone to Buprenorphine Using a Microdosing Approach: Unique Considerations at ASAM Level 3 Facilities. 

Anderson C, Cooley R, Patil D. 

J Addict Med. 2022 Sep 26. doi: 10.1097/ADM.0000000000001085. Epub ahead of print. PMID: 36161824.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36161824/

Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper. 

Bozinoff N, Men S, Kurdyak P, Selby P, Gomes T. 

JAMA Netw Open. 2022 Sep 1;5(9):e2234168. doi: 10.1001/jamanetworkopen.2022.34168. PMID: 36173629.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796830

Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation. 

Randall A, Hull I, Martin SA. 

J Addict Med. 2022 Sep 23. doi: 10.1097/ADM.0000000000001073. Epub ahead of print. PMID: 36149001.

https://journals.lww.com/journaladdictionmedicine/Fulltext/9900/Enhancing_Patient_Choice__Using_Self_administered.83.aspx

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings. 

Boyett B, Nadipelli VR, Solem CT, Chilcoat H, Bickel WK, Ling W. 

J Addict Med. 2022 Sep 16. doi: 10.1097/ADM.0000000000001070. Epub ahead of print. PMID: 36111991.

https://journals.lww.com/journaladdictionmedicine/Fulltext/9900/Continued_Posttrial_Benefits_of_Buprenorphine.77.aspx

Buprenorphine and its formulations: a comprehensive review. 

Poliwoda S, Noor N, Jenkins JS, Stark CW, Steib M, Hasoon J, Varrassi G, Urits I, Viswanath O, Kaye AM, Kaye AD. 

Health Psychol Res. 2022 Aug 20;10(3):37517. doi: 10.52965/001c.37517. PMID: 35999975; PMCID: PMC9392838.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9392838/

Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone. 

Marsden J, Kelleher M, Hoare Z, Hughes D, Bisla J, Cape A, Cowden F, Day E, Dewhurst J, Evans R, Hearn A, Kelly J, Lowry N, McCusker M, Murphy C, Murray R, Myton T, Quarshie S, Scott G, Turner S, Vanderwaal R, Wareham A, Gilvarry E, Mitcheson L. 

Trials. 2022 Aug 19;23(1):697. doi: 10.1186/s13063-022-06595-0. PMID: 35986418; PMCID: PMC9389497.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389497/

Thirty-day Treatment Continuation After Audio-only Buprenorphine Telehealth Initiation. 

Wunsch C, Wightman R, Pratty C, Jacka B, Hallowell BD, Clark S, Davis CS, Samuels EA. 

J Addict Med. 2022 Sep 14. doi: 10.1097/ADM.0000000000001077. Epub ahead of print. PMID: 36102540.

Abstract

https://pubmed.ncbi.nlm.nih.gov/36102540/

How the Suboxone Education Programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis. 

Sud A, Strang M, Buchman DZ, Spithoff S, Upshur REG, Webster F, Grundy Q. 

BMJ Open. 2022 Jul 12;12(7):e059561. doi: 10.1136/bmjopen-2021-059561. PMID: 35820738; PMCID: PMC9277368.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277368/

Outpatient Microdose Induction with Transdermal Buprenorphine: A Case Series. 

Menard S, Jhawar A. 

Healthcare (Basel). 2022 Jul 14;10(7):1307. doi: 10.3390/healthcare10071307. PMID: 35885833; PMCID: PMC9317019.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317019/

The Naloxone Component of Buprenorphine/Naloxone: Discouraging Misuse, but at What Cost? 

Gregg J, Hartley J, Lawrence D, Risser A, Blazes C. 

J Addict Med. 2022 Aug 1. doi: 10.1097/ADM.0000000000001030. Epub ahead of print. PMID: 35913990.

Abstract

https://journals.lww.com/journaladdictionmedicine/Abstract/9900/The_Naloxone_Component_of_Buprenorphine_Naloxone_.28.aspx

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province.

Sadek J, Saunders J. 

BMC Psychiatry. 2022 Jul 30;22(1):516. doi: 10.1186/s12888-022-04175-9. PMID: 35908052; PMCID: PMC9338516.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338516/

Development of an intravenous low-dose buprenorphine initiation protocol. 

Jablonski LA, Bodnar AR, Stewart RW. 

Drug Alcohol Depend. 2022 Aug 1;237:109541. doi: 10.1016/j.drugalcdep.2022.109541. Epub 2022 Jun 20. PMID: 35753281.

Abstract

https://www.sciencedirect.com/science/article/abs/pii/S0376871622002782

Depot buprenorphine: Safe and effective for clients in jails and prisons?

There are barriers to receiving opioid use disorder medications, such as buprenorphine, for individuals in criminal justice settings like jails and prisons. These include limited resources to ensure adequate medical monitoring and the potential for their illegal sharing or selling (i.e., diversion) to other inmates. This study examined safety and opioid use outcomes in a group of incarcerated individuals who received a longer acting, injection formulation of buprenorphine. (Recovery Research Institute, USA, Juli 2022)

https://www.recoveryanswers.org/research-post/depot-buprenorphine-safe-effective-clients-jails-prisons/

Treatment Choices: Buprenorphine

Exchange Supplies, UK. Third edition. oD

https://www.exchangesupplies.org/pdf/P802.pdf

Treatment Choices: Suboxone

Exchange Supplies, UK. Third edition. oD

https://www.exchangesupplies.org/pdf/P805.pdf

A Review of Novel Methods To Support The Transition From Methadone and Other Full Agonist Opioids To Buprenorphine/Naloxone Sublingual In Both Community and Acute Care Settings,

Ghosh, Sumantra Monty MD, MSc, FRCPC, ISAM1; Klaire, Sukhpreet MD, CCFP2; Tanguay, Robert MD, FRCPC, ISAM3; Manek, Mandy MD, CCFP4; Azar, Pouya MD, FRCPC, ISAM5

The Canadian Journal of Addiction: December 2019 - Volume 10 - Issue 4 - p 41-50, doi: 10.1097/CXA.0000000000000072

https://journals.lww.com/cja/fulltext/2019/12000/a_review_of_novel_methods_to_support_the.7.aspx

The Association between Buprenorphine Treatment Duration and Mortality: A Multi-site Cohort Study of People who Discontinued Treatment. 

Glanz JM, Binswanger IA, Clarke CL, Nguyen AP, Ford MA, Ray GT, Xu S, Hechter RC, Yarborough BJH, Roblin DW, Ahmedani B, Boscarino JA, Andrade SE, Rosa CL, Campbell CI. 

Addiction. 2022 Jul 11. doi: 10.1111/add.15998. Epub ahead of print. PMID: 35815386.

https://onlinelibrary.wiley.com/doi/epdf/10.1111/add.15998

  1. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. 
  2. Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020. 
  3. Identifying and Characterizing Medical Advice-Seekers on a Social Media Forum for Buprenorphine Use. 
  4. Patient perspectives on depot buprenorphine treatment for opioid addiction - a qualitative interview study. 
  5. Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia.